Maplight Therapeutics (NASDAQ:MPLT) CFO Sells $307,464.60 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) CFO Vishwas Setia sold 10,903 shares of the business’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $28.20, for a total transaction of $307,464.60. Following the sale, the chief financial officer owned 366,820 shares in the company, valued at $10,344,324. This trade represents a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vishwas Setia also recently made the following trade(s):

• On Wednesday, May 6th, Vishwas Setia sold 10,564 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.24, for a total transaction of $298,327.36.
• On Monday, May 4th, Vishwas Setia sold 14,904 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.11, for a total transaction of $418,951.44.

Maplight Therapeutics Price Performance

NASDAQ:MPLT traded up $1.12 during midday trading on Wednesday, hitting $29.04. 267,979 shares of the stock were exchanged, compared to its average volume of 342,018. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $33.28. The company has a market cap of $1.24 billion and a P/E ratio of -0.73. The company’s 50-day moving average price is $22.60.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). As a group, analysts forecast that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Maplight Therapeutics

Several hedge funds have recently modified their holdings of MPLT. Fcpm Iii Services B.V. acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at $56,672,000. T. Rowe Price Investment Management Inc. acquired a new stake in Maplight Therapeutics during the 4th quarter worth about $49,154,000. Goldman Sachs Group Inc. purchased a new stake in Maplight Therapeutics during the fourth quarter valued at about $34,026,000. Nan Fung Group Holdings Ltd purchased a new stake in Maplight Therapeutics during the fourth quarter valued at about $17,060,000. Finally, 5AM Venture Management LLC acquired a new position in shares of Maplight Therapeutics in the fourth quarter worth about $16,687,000.

Analysts Set New Price Targets

A number of research analysts recently issued reports on MPLT shares. HC Wainwright initiated coverage on Maplight Therapeutics in a report on Monday. They set a “buy” rating and a $45.00 target price on the stock. Weiss Ratings initiated coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Needham & Company LLC initiated coverage on shares of Maplight Therapeutics in a research report on Wednesday, April 8th. They set a “buy” rating and a $37.00 price objective for the company. Canaccord Genuity Group began coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Wall Street Zen downgraded shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.43.

Key Stories Impacting Maplight Therapeutics

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its “Buy” rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a “Buy” rating and a $45 price target (roughly mid‑50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50‑day moving average) that traders use to gauge technical support/resistance. Use these pages for up‑to‑date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright’s detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash‑burn and execution risk for a clinical‑stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow‑up data or guidance are weak. Recent Earnings Miss

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.